electroCore Commences Patient Enrollment for PTSD Clinical Study

electroCore, Inc. (Nasdaq: ECOR) has announced the enrollment of the first eight patients in a clinical study evaluating its gammaCore technology for the treatment of Post-Traumatic Stress Disorder (PTSD). The investigator-led study is being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society. This initiative utilizes the company's proprietary non-invasive vagus nerve stimulation (nVNS) technology to explore new therapeutic applications within the mental health sector. By targeting PTSD, electroCore aims to expand its clinical footprint and diversify its current medical device offerings. Clinical trial milestones are typically viewed as positive developments for micro-cap med-tech firms, signaling progress in research and development. While the immediate financial impact may be limited, successful outcomes could pave the way for broader commercial adoption of the gammaCore device in the future.